TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10969225

Group type: EXPERIMENTAL
Intervention: Docusate sodium
Number of subjects: 50

Group type: COMPARATOR
Intervention: Triethanolamine polypeptide
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Docusate sodium (in children aged 5 or less)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Triethanolamine polypeptide (in children aged 5 or less)
Number of subjects: 50
Study: 8695078

Group type: EXPERIMENTAL
Intervention: PCINA for 4 hours followed by 5 hours of ward‐provided pain therapy (Group 1; n = 10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ward‐provided pain therapy for 5 hours followed by 4 hours of PCINA (Group 2; n = 10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PCINA
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ward‐provided pain therapy
Number of subjects: 20
Study: 1355745

Group type: EXPERIMENTAL
Intervention: 8 mg acrivastine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 6369524

Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone (3.5 mg/kg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-dose methylprednisolone (1.0 mg/kg/day)
Number of subjects: 0
Study: 30269963

Group type: EXPERIMENTAL
Intervention: Capacitive resistive monopolar radiofrequency (CRMRF) treatment
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham-CRMRF treatment
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (standard care only)
Number of subjects: 45
Study: 30402840

Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization (TACE)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Radiofrequency ablation
Number of subjects: 62
Study: 26695724

Group type: COMPARATOR
Intervention: Weekly iron (100 mg), folic acid (500 mcg) and placebo for 26 weeks (Group A)
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Weekly iron (100 mg), folic acid (500 mcg) and cyanocobalamin (500 mcg for 6 weeks and 15 mcg for 20 weeks) for 26 weeks (Group B)
Number of subjects: 446
Study: 23761326

Group type: EXPERIMENTAL
Intervention: 400 IU of vitamin D3 daily
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: 800 IU of vitamin D3 daily
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: 1600 IU of vitamin D3 daily
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: 2400 IU of vitamin D3 daily
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study: 23107038

Group type: EXPERIMENTAL
Intervention: Combination exercise training
Number of subjects: 64
Study: 20163197

Group type: EXPERIMENTAL
Intervention: Extended-release niacin (ERN) 2 g + laropiprant (LRPT) 40 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extended-release niacin (ERN) 2 g
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laropiprant (LRPT) alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17631681

Group type: EXPERIMENTAL
Intervention: Artesunate plus sulphadoxine/pyrimethamine (AS/SP)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 160
Study: 15660039

Group type: EXPERIMENTAL
Intervention: Single-lead ST resolution (STR)
Number of subjects: 3030

Group type: COMPARATOR
Intervention: Sum STR
Number of subjects: 3030
Study: 11848169

Group type: EXPERIMENTAL
Intervention: Guanabenz (GB; 2-8 mg at 11 PM, n = 17)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (n = 17)
Number of subjects: 34
Study: 10448876

Group type: EXPERIMENTAL
Intervention: Cranial radiation (two doses)
Number of subjects: 474

Group type: COMPARATOR
Intervention: Clinician's impression (no progression)
Number of subjects: 474

Group type: COMPARATOR
Intervention: Clinician's impression (progression)
Number of subjects: 474
Study: 8543717

Group type: EXPERIMENTAL
Intervention: Brief prevention program (BP) consisting of 4 sessions of cognitive-behavioral therapy (CBT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Assessment control (AC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Brief prevention program (BP)
Number of subjects: 20
Study: 2337214

Group type: EXPERIMENTAL
Intervention: Local anaesthetic solution prewarmed to 37 degrees C
Number of subjects: 24

Group type: COMPARATOR
Intervention: Local anaesthetic solution at room temperature
Number of subjects: 24
Study: 463893

Group type: EXPERIMENTAL
Intervention: Abrupt discontinuation of lidocaine infusion (Group 1)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Gradual tapering of lidocaine infusion over a three-hour period (Group 2)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Lidocaine infusion for 36 hours or less
Number of subjects: 29

Group type: COMPARATOR
Intervention: Comparison of abrupt cessation versus three-hour tapering of lidocaine infusion
Number of subjects: 29
Study: 31721601

Group type: EXPERIMENTAL
Intervention: Inactivated varicella-zoster virus (VZV) vaccine (ZVIN)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study: 30935872

Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery with faster-acting insulin aspart
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional subcutaneous insulin therapy (control group)
Number of subjects: 43
Study: 28611343

Group type: EXPERIMENTAL
Intervention: PEG IFN 180 mcg weekly for 12 months (add-on therapy)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Tenofovir 300 mg orally daily (monotherapy)
Number of subjects: 48
Study: 24985348

Group type: EXPERIMENTAL
Intervention: Er:YAG laser irradiation
Number of subjects: 56

Group type: COMPARATOR
Intervention: Non-irradiated enamel slabs
Number of subjects: 56

Group type: COMPARATOR
Intervention: Deionized water immersion
Number of subjects: 56

Group type: COMPARATOR
Intervention: Citric acid immersion
Number of subjects: 56
Study: 22981698

Group type: EXPERIMENTAL
Intervention: One-session brief intervention (S1)
Number of subjects: 202
Study: 21317934

Group type: EXPERIMENTAL
Intervention: Oral azithromycin 250 mg daily for 12 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo daily for 12 weeks
Number of subjects: 22
Study: 19485594

Group type: EXPERIMENTAL
Intervention: Family Check-Up intervention
Number of subjects: 731

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 731
Study: 17048231

Group type: EXPERIMENTAL
Intervention: Decreased serum EGFR levels
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Decreased serum EGFR and normal serum HER-2
Number of subjects: 535

Group type: COMPARATOR
Intervention: Normal serum EGFR and HER-2
Number of subjects: 535
Study: 12735919

Group type: EXPERIMENTAL
Intervention: Experimental formulations of low calorie carbonated orange drinks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (conventional diet products and water)
Number of subjects: 15
Study: 11549101

Group type: EXPERIMENTAL
Intervention: 14C-cholesterol-labeled AmBisome (2 mg/kg, 1 microgCi/kg)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 14C-cholesterol-labeled AmBisome
Number of subjects: 5
Study: 10165099

Group type: EXPERIMENTAL
Intervention: Multicomponent behavioral smoking cessation program
Number of subjects: 93

Group type: COMPARATOR
Intervention: Self-help control condition
Number of subjects: 93
Study: 7879710

Group type: EXPERIMENTAL
Intervention: Whole herpes simplex vaccines
Number of subjects: 15000
Study: 2849775

Group type: EXPERIMENTAL
Intervention: Fentanyl 0.1 mg/70 kg
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Fentanyl 0.2 mg/70 kg
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Fentanyl 0.25 mg/70 kg
Number of subjects: 41

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 41
Study: 1520049

Group type: EXPERIMENTAL
Intervention: Educational materials (monograph, pamphlet, and audiotape) provided to physicians before the simulated patient visit.
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Use of the study risk assessment questionnaire during the simulated patient visit.
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: General patient interaction measures.
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Overall performance of physicians during the simulated patient visit.
Number of subjects: 232
Study: 603271

Group type: EXPERIMENTAL
Intervention: Low dose heparin (5000 units two hours before operation and 5000 units every 12 hours following operation for five days)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Low dose heparin postoperatively only
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 175
Study: 31655314

Group type: EXPERIMENTAL
Intervention: Deep tissue massage
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Supervised strengthening and stretching exercises
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Combined therapy (exercise followed by massage)
Number of subjects: 619

Group type: COMPARATOR
Intervention: Advice to stay active
Number of subjects: 619
Study: 31596865

Group type: EXPERIMENTAL
Intervention: HIV positive patients with CD4 count <200 cells/ul
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: HIV positive patients with CD4 count 200-350 cells/ul
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: HIV positive patients living with HIV ≥9 years
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: HIV positive patients living with HIV 5-8 years
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: HIV positive patients infected with intestinal parasites
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: HIV positive patients with BMI <18.5 kg/m2
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: HIV positive patients with BMI 18.5-25 kg/m2
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: HIV positive patients who are HAART naïve
Number of subjects: 411
Study: 28218556

Group type: EXPERIMENTAL
Intervention: Surgical protocol A (Trial 1)
Number of subjects: 448

Group type: COMPARATOR
Intervention: Surgical protocol A (Trial 2)
Number of subjects: 448

Group type: COMPARATOR
Intervention: Surgical protocol A (Trial 3)
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Girls (overall performance)
Number of subjects: 448
Study: 25561359

Group type: EXPERIMENTAL
Intervention: EG1 - Training focused on ball handling, balance, and manual dexterity
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: EG2 - Training in sports without a specific focus
Number of subjects: 43

Group type: COMPARATOR
Intervention: CG - Wait-list control group, no intervention
Number of subjects: 43
Study: 23786558

Group type: EXPERIMENTAL
Intervention: Continuous ketamine (0.2 mg/kg/hour)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Hydromorphone PCA and saline (Control)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both groups (Ketamine and Control)
Number of subjects: 64
Study: 21341148

Group type: EXPERIMENTAL
Intervention: Dexketoprofen 25 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 19843807

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance (US)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Neurostimulation (NS)
Number of subjects: 60
Study: 17524940

Group type: EXPERIMENTAL
Intervention: Orange juice
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tangerine juice
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water
Number of subjects: 10
Study: 12638394

Group type: EXPERIMENTAL
Intervention: Vardenafil 20 mg after overnight fast
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Vardenafil 20 mg after high-fat breakfast
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Vardenafil 20 mg on empty stomach in the evening
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Vardenafil 20 mg after moderate-fat meal in the evening
Number of subjects: 25
Study: 10879639

Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg bid on the 1st day, followed by 500 mg once daily for the next 4 days)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Doxycycline (100 mg bid for 14 days)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 48
Study: 8638462

Group type: EXPERIMENTAL
Intervention: E2V/MPA
Number of subjects: 51

Group type: COMPARATOR
Intervention: CE/MED
Number of subjects: 51
Study: 1378136

Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg b.i.d.)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Propranolol-ISDN (80 mg/20 mg b.i.d.)
Number of subjects: 31
Study: 6089614

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31659977

Group type: EXPERIMENTAL
Intervention: Elastic intramedullary nails
Number of subjects: 98
Study: 28555251

Group type: EXPERIMENTAL
Intervention: Milk protein supplement (SUPP)
Number of subjects: 10
Study: 26086284

Group type: EXPERIMENTAL
Intervention: Translaryngeal injection (TLI) technique
Number of subjects: 120

Group type: COMPARATOR
Intervention: Enk Fibreoptic Atomizer
Number of subjects: 120
Study: 23499273

Group type: EXPERIMENTAL
Intervention: Cystatin C levels in the highest quartile
Number of subjects: 423

Group type: COMPARATOR
Intervention: Cystatin C levels in the lower 3 quartiles
Number of subjects: 423
Study: 21584955

Group type: EXPERIMENTAL
Intervention: Alflutop (intramuscular injections) + peloid applications
Number of subjects: 94
Study: 19122088

Group type: EXPERIMENTAL
Intervention: Metal backing of the tibial component
Number of subjects: 2352

Group type: EXPERIMENTAL
Intervention: Patellar resurfacing
Number of subjects: 2352

Group type: EXPERIMENTAL
Intervention: Mobile bearing
Number of subjects: 2352

Group type: EXPERIMENTAL
Intervention: Total knee replacement (overall)
Number of subjects: 2352
Study: 16715016

Group type: EXPERIMENTAL
Intervention: Electrodiagnostic examination
Number of subjects: 150
Study: 14676530

Group type: EXPERIMENTAL
Intervention: Radiographic assessment of number of cortices
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Radiographic assessment for fixator removal
Number of subjects: 42
Study: 10878147

Group type: EXPERIMENTAL
Intervention: Cumulative sports-exercise scores between ages 12 and 18 years
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Time‐averaged daily calcium intake (500 to 1500 mg/day)
Number of subjects: 81
Study: 9132715

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 40

Group type: COMPARATOR
Intervention: Games
Number of subjects: 40

Group type: COMPARATOR
Intervention: School group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Home group
Number of subjects: 40
Study: 8410764

Group type: EXPERIMENTAL
Intervention: Prototype filament suspension design toothbrush (active suspension)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prototype filament suspension design toothbrush (inactive suspension)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional toothbrush
Number of subjects: 0
Study: 3516668

Group type: EXPERIMENTAL
Intervention: Cognitive‐Behavior Therapy
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Supportive Counseling
Number of subjects: 27

Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 27
Study: 30243867

Group type: EXPERIMENTAL
Intervention: Interventional group (group 2) - toys and video games for children, counseling and information for parents
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (group 1) - noninterventional
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Interventional group (group 2)
Number of subjects: 60
Study: 28275117

Group type: EXPERIMENTAL
Intervention: Parsatuzumab (400 mg) in combination with mFOLFOX6 plus bevacizumab (5 mg/kg)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo in combination with mFOLFOX6 plus bevacizumab (5 mg/kg)
Number of subjects: 127
Study: 25264670

Group type: COMPARATOR
Intervention: High-Intensity Resistance Training (HRT): 4 × 10 repetitions, 70-80% one repetition maximum (1RM)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Low-Intensity Resistance Training with Blood Flow Restriction (LRT-BFR): 4 sets (1 × 30 and 3 × 15 repetitions), 20-30% 1RM
Number of subjects: 23
Study: 23726657

Group type: EXPERIMENTAL
Intervention: Adenoidectomy with or without tonsillectomy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Healthy control group (no adenotonsillar disease)
Number of subjects: 35
Study: 22180731

Group type: EXPERIMENTAL
Intervention: Epilation
Number of subjects: 1300

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 1300
Study: 18222671

Group type: EXPERIMENTAL
Intervention: Aescin and troxerutin combination treatment
Number of subjects: 68

Group type: COMPARATOR
Intervention: Pentoxyfyllin
Number of subjects: 68
Study: 16838478

Group type: EXPERIMENTAL
Intervention: One-Step Plus (phosphoric acid conditioner)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (self-etching primer)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Comparison of One-Step Plus and Clearfil SE Bond
Number of subjects: 28
Study: 12725561

Group type: EXPERIMENTAL
Intervention: Standard dose of SHR-5 Rhodiola rosea extract (2 capsules)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Higher dose of SHR-5 Rhodiola rosea extract (3 capsules)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 11089761

Group type: EXPERIMENTAL
Intervention: Nebulized ET(A) receptor antagonist (LU‐135252, 3 mg/kg, inhaled over 1 h)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nebulization of saline (5-10 ml inhaled over 1 h)
Number of subjects: 16
Study: 9158351

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with 0.75% bupivacaine and general anesthesia (n = 6)
Number of subjects: 12

Group type: COMPARATOR
Intervention: General anesthesia with thiopentone, vecuronium, fentanyl, or enflurane (control group, n = 6)
Number of subjects: 12
Study: 8093824

Group type: EXPERIMENTAL
Intervention: Zuclopenthixol acetate
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Zuclopenthixol
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: All treatments (Zuclopenthixol acetate, Haloperidol, Zuclopenthixol)
Number of subjects: 143
Study: 3690045

Group type: EXPERIMENTAL
Intervention: High sodium intake (16 to 20 g)
Number of subjects: 17
Study: 29513635

Group type: EXPERIMENTAL
Intervention: Strip-type bleaching agent
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Paint-on-type bleaching agent
Number of subjects: 75

Group type: COMPARATOR
Intervention: Negative control (products without H2O2)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Positive control (dentist-supervised home bleaching)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: All treatment groups (strip, paint-on, and controls)
Number of subjects: 75
Study: 28682707

Group type: EXPERIMENTAL
Intervention: VAMOS group (behavior change program)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 25636028

Group type: EXPERIMENTAL
Intervention: Sticky mittens
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Non-sticky mittens
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 24
Study: 24122257

Group type: EXPERIMENTAL
Intervention: S-1 plus CIK
Number of subjects: 58

Group type: COMPARATOR
Intervention: S-1 alone (CT group)
Number of subjects: 58
Study: 20543751

Group type: EXPERIMENTAL
Intervention: Isomaltulose (ISO), 75 g, GI = 32
Number of subjects: 8
Study: 19032300

Group type: EXPERIMENTAL
Intervention: Phenylephrine 100 microg
Number of subjects: 204

Group type: COMPARATOR
Intervention: Ephedrine 10 mg
Number of subjects: 204
Study: 17138192

Group type: EXPERIMENTAL
Intervention: IA morphine 5 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: IA saline 1 mL (placebo)
Number of subjects: 60
Study: 12721242

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, doxorubicin, and cisplatin (CAP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carboplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclophosphamide and cisplatin (CP)
Number of subjects: 0
Study: 10848717

Group type: EXPERIMENTAL
Intervention: Antidepressants (specific agents not mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phase II and III clinical trial programme (specific agents not mentioned)
Number of subjects: 0
Study: 7758059

Group type: EXPERIMENTAL
Intervention: Diclofenac dispersible 50 mg three times daily for 3 to 7 days
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Diclofenac dispersible 50 mg
Number of subjects: 253

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study: 2204776

Group type: EXPERIMENTAL
Intervention: Methyldopa (250 mg b.i.d.)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Urapidil (30 mg b.i.d.)
Number of subjects: 20
Study: 386697

Group type: EXPERIMENTAL
Intervention: Proglumide (1200 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Magnesium trisilicate (1320 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Proglumide (1200 mg/day) and Magnesium trisilicate (1320 mg/day)
Number of subjects: 16
Study: 29596662

Group type: EXPERIMENTAL
Intervention: Breakout items for each product (B)
Number of subjects: 4100

Group type: EXPERIMENTAL
Intervention: Breakout items for each product with images (B + I)
Number of subjects: 4100

Group type: EXPERIMENTAL
Intervention: Checklist and breakout items (CL and B)
Number of subjects: 4100

Group type: EXPERIMENTAL
Intervention: Checklist and breakout items with images (CL and B + I)
Number of subjects: 4100

Group type: COMPARATOR
Intervention: Checklist (CL)
Number of subjects: 4100
Study: 27925466

Group type: EXPERIMENTAL
Intervention: Low-concentration iodinated contrast agent (270 mgI/ml) and low tube current (120 mA)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard dose protocol (370 mgI/ml) and conventional tube current (160 mA)
Number of subjects: 110
Study: 26079777

Group type: EXPERIMENTAL
Intervention: Perioperative Tight Glucose Control (TGC)
Number of subjects: 2383

Group type: COMPARATOR
Intervention: Postoperative Tight Glucose Control (TGC)
Number of subjects: 2383

Group type: EXPERIMENTAL
Intervention: Perioperative TGC in nondiabetic subjects
Number of subjects: 2383

Group type: COMPARATOR
Intervention: Postoperative TGC in nondiabetic subjects
Number of subjects: 2383

Group type: EXPERIMENTAL
Intervention: Perioperative TGC in diabetic patients
Number of subjects: 2383
Study: 24335524

Group type: EXPERIMENTAL
Intervention: Sea cucumber jelly (containing hydrolysate of Stichopus japonicus)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control jelly (without S. japonicus)
Number of subjects: 17